Hiroyuki Suzuki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7579170/publications.pdf

Version: 2024-02-01

		430874	414414
56	1,136	18	32
papers	citations	h-index	g-index
58	58	58	1526
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Case Report: Ciclosporin A for Refractory Multisystem Inflammatory Syndrome in Children. Frontiers in Pediatrics, 2022, 10, .	1.9	2
2	Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan. JAMA Network Open, 2022, 5, e2216642.	5.9	3
3	Candida guilliermondii-induced chorioretinitis in a patient with eating disorder. Journal of Infection and Chemotherapy, 2021, 27, 642-646.	1.7	5
4	Lipidomics links oxidized phosphatidylcholines and coronary arteritis in Kawasaki disease. Cardiovascular Research, 2021, 117, 96-108.	3.8	21
5	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. Journal of Clinical Medicine, 2021, 10, 987.	2.4	7
6	Z-score is a possible predictor of the risk of coronary artery lesion development in patients with Kawasaki disease in Japan. European Journal of Pediatrics, 2021, 180, 2797-2805.	2.7	6
7	Intimal thickening and disruption of the media occur in the arterial walls of coronary arteries not associated with coronary arterial aneurysms in patients with Kawasaki disease. BMC Cardiovascular Disorders, 2021, 21, 278.	1.7	8
8	Glycoprotein non–metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation. Cancer Science, 2021, 112, 4187-4197.	3.9	7
9	Characteristics and outcomes of avoidant/restrictive food intake disorder in Japanese elementaryâ€school students on total parenteral nutrition. Pediatric Investigation, 2021, 5, 293-298.	1.4	3
10	THG-1 suppresses SALL4 degradation to induce stemness genes and tumorsphere formation through antagonizing NRBP1 in squamous cell carcinoma cells. Biochemical and Biophysical Research Communications, 2020, 523, 307-314.	2.1	4
11	Promotion of cellular senescence by THG-1/TSC22D4 knockout through activation of JUNB. Biochemical and Biophysical Research Communications, 2020, 522, 897-902.	2.1	7
12	Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 127-134.	4.2	37
13	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. British Journal of Cancer, 2020, 122, 340-347.	6.4	24
14	Promotion of liver regeneration and antiâ€'fibrotic effects of theÂTGFâ€Î² receptor kinase inhibitor galunisertib in CCl4â€'treated mice. International Journal of Molecular Medicine, 2020, 46, 427-438.	4.0	13
15	Generation of non-standard macrocyclic peptides specifically binding TSC-22 homologous gene-1. Biochemical and Biophysical Research Communications, 2019, 516, 445-450.	2.1	4
16	Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet, The, 2019, 393, 1128-1137.	13.7	142
17	Investigation of novel variations of ORAI1 gene and their association with Kawasaki disease. Journal of Human Genetics, 2019, 64, 511-519.	2.3	9
18	The possible repositioning of an oral anti-arthritic drug, auranofin, for Nrf2-activating therapy: The demonstration of Nrf2-dependent anti-oxidative action using a zebrafish model. Free Radical Biology and Medicine, 2018, 115, 405-411.	2.9	9

#	Article	IF	CITATIONS
19	Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination. Cancer Immunology, Immunotherapy, 2018, 67, 949-964.	4.2	30
20	Significance of testing for TP53 gene mutations in lung adenocarcinoma using targeted gene sequencing. Journal of Thoracic Disease, 2018, 10, S4147-S4150.	1.4	2
21	Quantitative analysis and clonal characterization of T-cell receptor \hat{l}^2 repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine. Oncology Letters, 2017, 14, 283-292.	1.8	6
22	Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma. Lung Cancer, 2017, 114, 23-30.	2.0	12
23	Cyclosporin A for IVIG Nonresponders. , 2017, , 187-194.		O
24	\hat{l}^2 -Cell-Specific Mafk Overexpression Impairs Pancreatic Endocrine Cell Development. PLoS ONE, 2016, 11, e0150010.	2.5	4
25	FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. World Journal of Surgical Oncology, 2016, 14, 238.	1.9	25
26	Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 216-222.	1.1	13
27	Ground-glass nodule in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-positive lung cancer: a case report. World Journal of Surgical Oncology, 2016, 14, 81.	1.9	0
28	Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report. Case Reports in Oncology, 2016, 9, 51-55.	0.7	6
29	Role of PET/Computed Tomography in Radiofrequency Ablation for Malignant Pulmonary Tumors. PET Clinics, 2016, 11, 47-55.	3.0	3
30	Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer. Journal of Cancer Research and Therapeutics, 2016, 12, 945.	0.9	37
31	FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma. International Journal of Oncology, 2015, 46, 999-1006.	3.3	47
32	Prognostic Impact of Hypoxia-Inducible <i>miRNA-210</i> ii Patients with Lung Adenocarcinoma. Journal of Oncology, 2015, 2015, 1-8.	1.3	31
33	Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial). BMJ Open, 2015, 5, e009562.	1.9	27
34	Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer. Lung Cancer, 2015, 88, 310-318.	2.0	50
35	Recent advances in immunotherapy for non-small-cell lung cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 352-357.	3.3	16
36	Evaluation of Coronary Arterial Lesions Due to Kawasaki Disease Using Optical Coherence Tomography. Canadian Journal of Cardiology, 2014, 30, 956.e7-956.e9.	1.7	10

#	Article	IF	CITATIONS
37	Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer. Molecular and Clinical Oncology, 2014, 2, 685-694.	1.0	44
38	Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease. Cytokine, 2012, 60, 681-685.	3.2	38
39	Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin. Pediatric Infectious Disease Journal, 2011, 30, 871-876.	2.0	121
40	Marker of Tâ€eell activation is elevated in refractory Kawasaki disease. Pediatrics International, 2010, 52, 785-789.	0.5	16
41	Detection of Multiple Superantigen Genes in Stools of Patients with Kawasaki Disease. Journal of Pediatrics, 2009, 155, 266-270.	1.8	26
42	Prognostic impact of p53 protein overexpression in patients with node-negative lung adenocarcinoma. Cancer Letters, 2006, 237, 242-247.	7.2	9
43	A case of syndrome of inappropriate antidiuretic hormone (SIADH) after the resection of lung cancer. The Journal of the Japanese Association for Chest Surgery, 2006, 20, 180-183.	0.0	0
44	A 5-year survival case of so-called pulmonary carcinosarcoma with metastatic gastric tumor. The Journal of the Japanese Association for Chest Surgery, 2006, 20, 161-165.	0.0	1
45	Neoplasms in three patients following Kawasaki disease. Pediatrics International, 2005, 47, 217-219.	0.5	7
46	T Cell–Dependent Antibody Responses against Aberrantly Expressed Cyclin B1 Protein in Patients with Cancer and Premalignant Disease. Clinical Cancer Research, 2005, 11, 1521-1526.	7.0	92
47	Water retention in the acute phase of Kawasaki disease: relationship between oedema and the development of coronary arterial lesions. European Journal of Pediatrics, 2003, 162, 856-859.	2.7	10
48	Relation of Streptococcal Pyrogenic Exotoxin C as a Causative Superantigen for Kawasaki Disease. Pediatric Research, 2003, 53, 403-410.	2.3	42
49	Expression of peanut agglutinin-binding carbohydrates correlates with nodal involvement in human lung adenocarcinoma. Cancer Letters, 2002, 187, 215-221.	7.2	10
50	Detection of auto-antibodies against a 70ÂkDa protein derived from vascular smooth muscle cells in patients with Kawasaki disease. European Journal of Pediatrics, 2002, 161, 324-329.	2.7	5
51	Serum levels of neutrophil activation cytokines in Kawasaki disease. Pediatrics International, 2001, 43, 115-119.	0.5	36
52	A case of thoracoscopic resection of pulmonary alveolar soft part sarcoma The Journal of the Japanese Association for Chest Surgery, 2000, 14, 631-636.	0.0	0
53	Analysis of results of surgery performed over a 20-year period on 500 patients with cancer of the thoracic esophagus. Surgery Today, 1996, 26, 77-82.	1.5	32
54	Double Cancer of the Stomach and the Papilla of Vater. Progress of Digestive Endoscopy(1972), 1995, 47, 194-195.	0.0	0

HIROYUKI SUZUKI

#	Article	IF	CITATIONS
55	CLINICAL CONSIDERATION CONCERNING SURGICAL TREATMENT FOR MALIGNANT TUMORS EXTENDING INTO THE HEPATIC INFERIOR VENA CAVA. The Journal of the Japanese Practical Surgeon Society, 1990, 51, 2405-2411.	0.0	0
56	Changes in nuclear DNA and RNA during epidermal keratinization. Cell and Tissue Research, 1977, 184, 155-67.	2.9	17